Intuitive Surgical posts Q3 2026 revenue up 22% and reports $450M litigation charge
Intuitive Surgical reported third‑quarter 2026 revenue of $3.05 billion, a 22% year‑over‑year increase, while worldwide procedures rose about 15% with da Vinci up 14% and Ion up 31%. GAAP net income was $523 million ($1.49 per share) and non‑GAAP net income $1.05 billion ($3.00 per share), both impacted by a $450 million pre‑tax antitrust litigation charge. The company placed 546 da Vinci and 56 Ion systems, ending the quarter with $6.80 billion cash and repurchasing 7.8 million shares for $2.94 billion. It guided full‑year da Vinci procedure growth of 14%‑15% and a non‑GAAP gross margin of 68.7%‑69.3%.
Why it matters
The company expects procedure growth of 14%‑15% for 2026, which should support revenue expansion (the company says). The $2.94 billion share repurchase reduces cash and may affect liquidity (the filing reports the repurchase).
Key facts
- 1Q3 2026 revenue was $3.05 billion, up 22% YoY. stocktitan.net
- 2Worldwide procedures grew approximately 15% YoY; da Vinci procedures grew about 14% and Ion procedures about 31%. stocktitan.net
- 3The company placed 546 da Vinci surgical systems and 56 Ion endoluminal systems in the quarter. stocktitan.net
- 4GAAP net income attributable to Intuitive was $523 million, or $1.49 per diluted share. stocktitan.net
- 5Non‑GAAP net income attributable to Intuitive was $1.05 billion, or $3.00 per diluted share. stocktitan.net
- 6Results included a $450 million pre‑tax litigation charge related to an antitrust class‑action settlement. stocktitan.net
Summary written by AlphAI AI Desk from 5 of 5 sources. Not investment advice. Figures are as stated by the linked sources.